Publications by authors named "J Rousse"

Article Synopsis
  • Recent research tested a new treatment called LIS1, derived from genetically modified pigs, to see if it could safely be used in kidney transplant patients instead of traditional rabbit-derived antithymocyte globulins (ATGs).
  • The study showed that LIS1 effectively depleted T cells without causing major side effects, such as cytokine release syndrome, and was well tolerated by patients.
  • Results indicated that LIS1 has a long half-life and allows for quick recovery of lymphocyte counts, suggesting it could be a promising alternative for transplant immunosuppression.
View Article and Find Full Text PDF

The structure and decay of the most neutron-rich beryllium isotope, ^{16}Be, has been investigated following proton knockout from a high-energy ^{17}B beam. Two relatively narrow resonances were observed for the first time, with energies of 0.84(3) and 2.

View Article and Find Full Text PDF
Article Synopsis
  • Polyclonal rabbit antithymocyte globulins (ATGs) used in organ transplants can cause unwanted inflammation, while LIS1, a new generation of antilymphocyte globulins derived from genetically modified pigs, aims to reduce these risks.
  • A phase 1 study tested LIS1 in kidney transplant patients to assess its safety, T cell depletion effects, and pharmacokinetics.
  • Results indicated that LIS1 was well tolerated, effectively depleted T cells in certain dosage groups, and did not provoke severe side effects or the formation of antidrug antibodies.
View Article and Find Full Text PDF

Heterologous polyclonal antibodies (pAb) were shown to possess oncolytic properties a century ago with reported clinical responses. More recent preclinical models confirmed pAb efficacy, though their ability to tackle complex target antigens reduces susceptibility to tumor escape. Owing to the recent availability of glyco-humanized pAb (GH-pAb) with acceptable clinical toxicology profile, we revisited use of pAb in oncology and highlighted their therapeutic potential against multiple cancer types.

View Article and Find Full Text PDF

Anti-thymocyte or anti-lymphocyte globulins (ATGs/ALGs) are immunosuppressive drugs used in induction therapies to prevent acute rejection in solid organ transplantation. Because animal-derived, ATGs/ALGs contain highly immunogenic carbohydrate xenoantigens eliciting antibodies that are associated with subclinical inflammatory events, possibly impacting long-term graft survival. Their strong and long-lasting lymphodepleting activity also increases the risk for infections.

View Article and Find Full Text PDF